AKTS
Aktis Oncology, Inc.
Key Financials
Net Income
$-18325000
N/A
Operating Income
$-22706000
N/A
Revenue
$3.2M
N/A
EPS (Diluted)
$-0.38
N/A
Total Assets
$576.8M
N/A
Total Liabilities
$70.7M
N/A
Shareholders' Equity
$506.1M
N/A
Cash & Equivalents
$371.6M
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 5/14/2026 | View on SEC |
| 10-Q | 5/11/2026 | View on SEC |
| 8-K | 5/11/2026 | View on SEC |
| 4 | 4/16/2026 | View on SEC |
| 3 | 4/16/2026 | View on SEC |
| 8-K | 4/16/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
| 10-K | 3/30/2026 | View on SEC |
| SCHEDULE 13D | 1/20/2026 | View on SEC |
| SCHEDULE 13D | 1/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AKTS |
| Company Name | Aktis Oncology, Inc. |
| CIK | 2035832 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 978-237-4380 |